<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Dialogues Clin Neurosci</journal-id><journal-id journal-id-type="iso-abbrev">Dialogues Clin Neurosci</journal-id><journal-id journal-id-type="pmc">Dialogues Clin Neurosci</journal-id><journal-title-group><journal-title>Dialogues in Clinical Neuroscience</journal-title></journal-title-group><issn pub-type="ppub">1294-8322</issn><issn pub-type="epub">1958-5969</issn><publisher><publisher-name>Les Laboratoires Servier</publisher-name><publisher-loc>France</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6787535</article-id><article-id pub-id-type="pmid">31636493</article-id><article-id pub-id-type="doi">10.31887/DCNS.2019.21.2/vhede</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Treating psychiatric symptoms and disorders with
non-psychotropic medications&#x02029;</article-title><trans-title-group xml:lang="es"><trans-title>spanish title</trans-title></trans-title-group><trans-title-group xml:lang="fr"><trans-title>french title</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hede</surname><given-names>Vincent</given-names></name><degrees>MD</degrees><aff>Author affiliations: Liaison Psychiatry Unit (Vincent Hede); Young Adult
Psychiatry Unit (C&#x000e9;dric Devill&#x000e9;); Department of Psychiatry, Geneva University
Hospitals, Geneva, Switzerland. Address for correspondence: Dr Vincent Hede,
H&#x000f4;pitaux Universitaires de Gen&#x000e8;ve, Rue Gabrielle-Perret-Gentil 4, 1205 Geneva,
Switzerland. (e-mail: Vincent.Hede@hcuge.ch)</aff></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Devill&#x000e9;</surname><given-names>C&#x000e9;dric</given-names></name><degrees>MD</degrees><aff>Author affiliations: Liaison Psychiatry Unit (Vincent Hede); Young Adult
Psychiatry Unit (C&#x000e9;dric Devill&#x000e9;); Department of Psychiatry, Geneva University
Hospitals, Geneva, Switzerland. Address for correspondence: Dr Vincent Hede,
H&#x000f4;pitaux Universitaires de Gen&#x000e8;ve, Rue Gabrielle-Perret-Gentil 4, 1205 Geneva,
Switzerland. (e-mail: Vincent.Hede@hcuge.ch)</aff></contrib></contrib-group><author-notes><corresp id="COR1">Dr Vincent Hede, H&#x000f4;pitaux Universitaires de Gen&#x000e8;ve, Rue
Gabrielle-Perret-Gentil 4, 1205 Geneva, Switzerland.<label>*</label> E-mail:
<email>Vincent.Hede@hcuge.ch</email></corresp></author-notes><pub-date pub-type="epub-ppub"><month>6</month><year>2019</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><month>6</month><year>2019</year></pub-date><volume>21</volume><issue>2</issue><fpage>193</fpage><lpage>201</lpage><permissions><copyright-statement>&#x000a9; 2019, AICH &#x02013; Servier Group&#x0feff;Copyright &#x000a9; 2019 AICH &#x02013; Servier Group.
All rights reserved</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative
Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link>), which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p></license></permissions><abstract><p>A few drugs prescribed in internal medicine, ie, non-psychotropic drugs, can be used
to treat certain neuropsychiatric disorders. For most of these situations, the level
of evidence remains low. But when sufficient data becomes available, these molecules
are then included in official guidelines for the treatment of neuropsychiatric
disorders. In this article we review interesting drugs which may be relevant from an
evidence-based medicine point of view, and could become part of psychiatric practice
in the future.&#x02029;</p></abstract><trans-abstract xml:lang="es"><p>Mettre la traduction ES</p></trans-abstract><trans-abstract xml:lang="fr"><p>Mettre la traduction FR</p></trans-abstract><kwd-group><kwd><italic>non-psychotropic medication</italic></kwd><kwd><italic>psychiatric disorder</italic></kwd><kwd><italic>psychopharmacology</italic></kwd><kwd><italic>evidence-based medicine</italic></kwd></kwd-group></article-meta></front><body><sec><title>Introduction&#x02029;</title><p>
Psychotropic medications (PMs) are, according to a formal definition, drugs
that affect mental and psychological functions. Many non-psychotropic medications
(non-PMs) prescribed for physical (ie, non-psychiatric) diseases also influence brain
function, and this influence can be beneficial. In this review, we label as non-PM all
drugs for which the main indication does not belong to the field of psychiatry. Here, we
discuss several non-PMs that are or might be useful in psychiatry, by improving a
psychiatric disorder or symptom in the absence of any physical disease. These benefits
have either been known for decades or they are new observations, as with statins. These
situations share a common point which concerns the confirmation and validation of non-PM
use in psychiatry; this path toward evidence-based medicine is sometimes tortuous.&#x02029; </p><p>
The study of these molecules has several advantages. First, it provides
alternative drugs, which can be scarce in psychiatry. They can be alternatives with
fewer side effects in disorders for which there already exist treatments, or
alternatives for disorders for which there are no sufficiently efficacious drugs, such
as in Alzheimer disease (AD), or autism spectrum disorder (ASD). Second, these molecules
have been used for a long time, and there is consequent knowledge about the tolerance
and risk profile. Third, it provides potential new drug indications with minimal
development cost. Fourth, using non-PMs to treat psychiatric disorders necessarily leads
to questioning their mechanisms of action and, in so doing, lead to a better
understanding of the pathophysiology of psychiatric disorders.&#x02029; </p></sec><sec><title>Non-psychotropic medications and psychiatric disorders&#x02029;</title><p>
Several non-PMs influence the course of a psychiatric disorder in patients
who do not suffer from the physical diseases for which these non-PMs are indicated.
Drugs like &#x003b2;-blockers are known for their effect against anxiety, while others, like
antibiotics (such as minocycline), are recent additions to the psychiatric field. In the
list below, we focus on several molecules for which there is some evidence of efficacy
(the development of non-PMs for neuropsychiatric clinical indications has the advantage
for the pharmaceutical industry of a less costly drug development process). Some
examples below might be new to some readers, while other non-PMs have been known to be
prescribed in psychiatry for decades.&#x02029; </p></sec><sec><title>Acetylsalicylic acid and other nonsteroidal &#x02028;anti-inflammatory drugs&#x02029;</title><p>
There is evidence for a role of inflammation, oxidative and nitrosative
stress, and mitochondrial dysfunction in disorders such as depression, schizophrenia,
bipolar disorder, and AD. <sup><xref rid="ref1" ref-type="bibr">1</xref></sup>
Acetylsalicylic acid and other nonsteroidal anti-inflammatory drugs
(NSAIDs) protect against oxidative damage, and have shown beneficial effects on mood
disorders. <sup><xref rid="ref2" ref-type="bibr">2</xref></sup>
, <sup><xref rid="ref3" ref-type="bibr">3</xref></sup>
A moderate antidepressant effect was observed for adjuvant NSAIDs compared
with conventional therapy alone in the treatment of bipolar depression. <sup><xref rid="ref4" ref-type="bibr">4</xref></sup>
A systematic review and meta-analysis of randomized clinical trials (RCTs)
suggests that NSAIDs, in particular celecoxib, decrease depressive symptoms without
increased risks of adverse effects. <sup><xref rid="ref5" ref-type="bibr">5</xref></sup>
Further trials are needed before making recommendations about the clinical
use of anti-inflammatory drugs in the treatment of mood disorders. <sup><xref rid="ref6" ref-type="bibr">6</xref></sup>
Very preliminary clinical work also suggests some efficacy of
acetylsalicylic acid in schizophrenia. <sup><xref rid="ref7" ref-type="bibr">7</xref></sup>
&#x02029; </p><p>
Epidemiological data show that patients who take NSAIDs long-term are at
lower risk of AD, and NSAIDs have generated enthusiasm for reducing the risk of AD. <sup><xref rid="ref8" ref-type="bibr">8</xref></sup>
However, clinical trials to date have shown no superiority over placebo
for sulindac, piroxicam, acetaminophen, naproxen, nabumetone, ketoprofen, diclofenac, or
acetylsalicylic acid. <sup><xref rid="ref9" ref-type="bibr">9</xref></sup>
The prescription of NSAIDs cannot be recommended for either prevention or
treatment of AD.&#x02029; </p></sec><sec><title>Bumetanide&#x02029;</title><p>
The diuretic bumetanide decreases intraneuronal chloride concentration and
thereby facilitates &#x003b3;-aminobutyric acid (GABA) inhibition. In animal models of ASD,
bumetanide restores intraneuronal chloride levels, enhances GABAergic inhibition, and
attenuates behavioral symptoms. In a phase II trial, bumetanide reduced the severity of
ASD in children and adolescents. <sup><xref rid="ref10" ref-type="bibr">10</xref></sup>
A case report suggests that long-term treatment reduced hallucinations and
that this treatment may also be useful to treat schizophrenia. <sup><xref rid="ref11" ref-type="bibr">11</xref></sup>
However, this was not confirmed in a later small double-blind study. <sup><xref rid="ref12" ref-type="bibr">12</xref></sup>
&#x02029; </p></sec><sec><title>Clonidine and other &#x003b1;-blockers&#x02029;</title><p>
The antihypertensive clonidine is a central &#x003b1;-2 agonist that also acts
through imidazoline receptors. <sup><xref rid="ref13" ref-type="bibr">13</xref></sup>
Guanfacine has the same mode of action, but with less sedation. Both were
approved as antihypertensives by the Food and Drug Administration (FDA) in 1974 and
1986. In 2010, they were registered for the treatment of attention-deficit hyperactivity
disorder (ADHD) in a pediatric population (6 to 17 years). Both are listed in ADHD
treatment guidelines. <sup><xref rid="ref14" ref-type="bibr">14</xref></sup>
They are also efficacious in opiate withdrawal, alcohol withdrawal, and
smoking cessation, and have been studied in Tourette syndrome, with benefits on behavior
and tics. <sup><xref rid="ref15" ref-type="bibr">15</xref></sup>
Clonidine is effective in smoking cessation. <sup><xref rid="ref16" ref-type="bibr">16</xref></sup>
It could also reduce traumatic memories and nightmares in patients with
post-traumatic stress disorder (PTSD). A systematic review found slight but positive
evidence for prazosin, an &#x003b1;-1 blocker, for the treatment of nightmares in PTSD. <sup><xref rid="ref17" ref-type="bibr">17</xref></sup>
&#x02029; </p></sec><sec><title>Gabapentin and other anticonvulsants&#x02029;</title><p>
The antiepileptics valproic acid, lamotrigine, and carbamazepine have a
recognized role in psychiatry that will not be commented on here. Gabapentin inhibits
the &#x003b1;2&#x003b4; subunit of voltage-dependent calcium channels. It is indicated for neuralgias,
restless leg syndrome, and partial seizures. It has shown efficacy in alcohol craving,
alcohol withdrawal, and several anxiety disorders including social anxiety. <sup><xref rid="ref18" ref-type="bibr">18</xref></sup>
Its close compound pregabalin has been registered in the United States for
use in social anxiety, fibromyalgia, and generalized anxiety.&#x02029; </p></sec><sec><title>Hydroxyzine and other antihistamines&#x02029;</title><p>
The first antihistamines used against allergic conditions are antagonists
to the histamine H1 receptor, which have also long been prescribed as sleeping pills;
diphenhydramine and several other antihistamines have been registered in many countries
as over the counter (OTC) sleeping pills. <sup><xref rid="ref19" ref-type="bibr">19</xref></sup>
Hydroxyzine was registered by the FDA a long time ago, in 1956, for the
symptomatic relief of anxiety; the results are considered equivalent to those of other
anxiolytics such as benzodiazepines in terms of efficacy, acceptability, and
tolerability, but this indication is recommended by only a few authors. <sup><xref rid="ref20" ref-type="bibr">20</xref></sup>
Hydroxyzine, like other early antihistamines, has anticholinergic and
antidopaminergic effects that participate in the side effect profile. The more recent
H1-blockers such as cetirizine or loratadine have not been studied as sleeping pills,
although cetirizine induces some sedation. Pitolisant, an antagonist to the H3 receptor,
has been registered in several countries to treat narcolepsy. The H3 receptors being
presynaptic, their blockade leads to more histamine and other neurotransmitters being
released, and pitolisant and other H3 antagonists are being studied as nootropic
agents.&#x02029; </p></sec><sec><title>Ketamine and other glutamatergic antagonists&#x02029;</title><p>
Ketamine is a nonselective NMDA glutamatergic receptor antagonist. While
GABA serves as the main site-to-site (ie, with rather short axons) inhibitory
transmitter, glutamate is the main excitatory site-to-site one, with too much glutamate
release leading to neurotoxicity. Ketamine is used in anesthesia and for the management
of post-surgery pain. Several randomized controlled trials (RCTs) of intravenous
ketamine provide findings of efficacy in treatment-resistant depression, bipolar
depression, and suicidal ideation. <sup><xref rid="ref21" ref-type="bibr">21</xref></sup>
Intranasal esketamine, the S enantiomer of ketamine, was accepted in early
2019 by the FDA for treatment-resistant depression. <sup><xref rid="ref22" ref-type="bibr">22</xref></sup>
Amantadine, a weak NMDA receptor antagonist with antiviral properties, can
play a role alone or in association with cholinesterase inhibitors to enhance cognitive
function and reduce behavioral symptoms in AD. <sup><xref rid="ref23" ref-type="bibr">23</xref></sup>
&#x02029; </p></sec><sec><title>Minocycline and other antibiotics&#x02029;</title><p>
Minocycline is a tetracycline bacteriostatic antibiotic. Apart from its
antibacterial properties, minocycline has anti-inflammatory, antiapoptotic, and
neuroprotective effects. <sup><xref rid="ref24" ref-type="bibr">24</xref></sup>
Minocycline might be useful in major depressive disorder (MDD) and in
bipolar depression. <sup><xref rid="ref25" ref-type="bibr">25</xref></sup>
- <sup><xref rid="ref27" ref-type="bibr">27</xref></sup>
A link between high level of Il-6 or brain glutathione and a better
response to minocycline is supposed. The clinical effects of adjunctive minocycline on
the negative symptoms of schizophrenia are controversial, <sup><xref rid="ref28" ref-type="bibr">28</xref></sup>
, <sup><xref rid="ref29" ref-type="bibr">29</xref></sup>
although a recent meta-analysis shows positive results. <sup><xref rid="ref30" ref-type="bibr">30</xref></sup>
&#x02029; </p><p>
Rifampicin inhibits bacterial RNA polymerase. It inhibits the formation of
amyloid-&#x003b2;, tau protein and &#x003b1;-synuclein, with promising results in animal models of AD. <sup><xref rid="ref31" ref-type="bibr">31</xref></sup>
, <sup><xref rid="ref32" ref-type="bibr">32</xref></sup>
The progression of AD might be slowed with rifampicin associated with
doxycycline or rifampicin alone. <sup><xref rid="ref33" ref-type="bibr">33</xref></sup>
, <sup><xref rid="ref34" ref-type="bibr">34</xref></sup>
These results were not confirmed in other trials, maybe because of dose
and length of treatment issues. <sup><xref rid="ref35" ref-type="bibr">35</xref></sup>
, <sup><xref rid="ref36" ref-type="bibr">36</xref></sup>
&#x02029; </p></sec><sec><title>N-Acetylcysteine and over-the-counter drugs&#x02029;</title><p>
N-acetylcysteine (NAC) is prescribed for its mucolytic effects and as
antidote in cases of acetaminophen overdose by providing a precursor for the glutathione
synthetase pathway. <sup><xref rid="ref37" ref-type="bibr">37</xref></sup>
The rationale for studying NAC in psychiatry is based on its interference
with several signaling pathways that play a role in regulating apoptosis, angiogenesis,
cell growth and inflammatory pathways, as well as on its modulatory action on
glutamatergic and dopaminergic systems. <sup><xref rid="ref38" ref-type="bibr">38</xref></sup>
The efficacy of NAC was discussed in an extensive review which considers
an astonishingly long list of psychiatric disorders, with the conclusion that no firm
recommendation could be given yet for NAC in any indication. <sup><xref rid="ref39" ref-type="bibr">39</xref></sup>
The highest evidence, (at least one prospective high-quality RCT) were
found for dependency treatment (cannabis, cocaine, and nicotine), unipolar and bipolar
depression, schizophrenia, and trichotillomania. According to a 2018 meta-analysis,
adjunctive NAC has efficacy in schizophrenia, but not in mood disorders or major
depressive disorder. <sup><xref rid="ref40" ref-type="bibr">40</xref></sup>
Further high-quality RCTs are warranted to determine the role of
adjunctive NAC in the treatment of major psychiatric disorders.&#x02029; </p><p>
S-adenosyl-L-methionine (SAMe), sold as a dietary supplement in United
States and Canada, is an endogenous, intracellular amino acid metabolite involved in
multiple crucial biochemical pathways, including biosynthesis of hormones and
neurotransmitters. During the 1970s and 1980s, SAMe was studied after intravenous
administration. A review of SAMe in major depression found limited evidence of efficacy
to support its use as a monotherapy or as augmentation with other antidepressants; the
authors were optimistic, but recognized that studies were of insufficient methodological
quality. <sup><xref rid="ref41" ref-type="bibr">41</xref></sup>
&#x02029; </p><p>
Tryptophan and hydroxytryptophan (5-HTP), amino acids that are precursors
of serotonin, are sometimes called natural alternatives to traditional antidepressants,
but they are less effective and safety concerns have not been clarified. <sup><xref rid="ref42" ref-type="bibr">42</xref></sup>
&#x02029; </p></sec><sec><title>Pramipexole and other antiparkinsonian drugs&#x02029;</title><p>
Pramipexole is a dopamine D2 and D3 receptor agonist indicated in Parkinson
disease (PD) and restless legs syndrome. Pramipexole is effective in unipolar and
bipolar depression in association with antidepressants or mood stabilizers. <sup><xref rid="ref43" ref-type="bibr">43</xref></sup>
It has also been studied in monotherapy with results comparable to
fluoxetine, but with side effects at high doses. <sup><xref rid="ref44" ref-type="bibr">44</xref></sup>
Most data concern its use as augmentation treatment for which low or
moderate doses up to 1.5 mg are sufficient with good safety concerns. The rate of manic
or hypomanic switch is also very low and pramipexole is quoted as an option for bipolar
depression in guidelines. <sup><xref rid="ref45" ref-type="bibr">45</xref></sup>
In drug-resistant depression, it is an alternative to other treatments
(lithium, aripiprazole, or quetiapine) with easier use and fewer side effects.&#x02029; </p><p>
Other antiparkinsonian drugs, such as ropinirole, pergolide, and
bromocriptine, have been less extensively studied in depression. Very anecdotally, in a
small case series dating back 50 years, delusional depression responded to L-dopa, while
nowadays delusion would be a contraindication to dopamine agonists. <sup><xref rid="ref46" ref-type="bibr">46</xref></sup>
&#x02029; </p></sec><sec><title>Propranolol and other &#x003b2;-blockers&#x02029;</title><p>
These cardiovascular medications reduce sympathetic nervous system activity
by blocking &#x003b2;-adrenergic receptors. Lipophilic &#x003b2;-blockers pass the blood-brain barrier,
which is the case with propranolol. <sup><xref rid="ref47" ref-type="bibr">47</xref></sup>
, <sup><xref rid="ref48" ref-type="bibr">48</xref></sup>
Aside from cardiovascular indications, migraine, and essential tremor,
propranolol might be useful in panic attacks. <sup><xref rid="ref49" ref-type="bibr">49</xref></sup>
Also, a meta-analysis showed no difference between propranolol and
benzodiazepines on anxiety, panic attack frequency, and avoidance behavior, although
equivalence was not proven. <sup><xref rid="ref50" ref-type="bibr">50</xref></sup>
Several studies showed that propranolol decreased apprehension before
diagnostic tests or dental interventions and some clinicians prescribe it to persons in
stressing situations, like exams, playing music, or acting, with the benefit of no
sedation. Since &#x003b2;-blockers inhibit memory consolidation, propranolol has been studied in
PTSD prevention. <sup><xref rid="ref51" ref-type="bibr">51</xref></sup>
- <sup><xref rid="ref53" ref-type="bibr">53</xref></sup>
Studies on how soon it should be administered after a trauma are ongoing.
A recent RCT concluded that propranolol associated with brief memory reactivation had
significant results compared with placebo in the treatment of PTSD. <sup><xref rid="ref54" ref-type="bibr">54</xref></sup>
&#x02029; </p></sec><sec><title>Statins&#x02029;</title><p>
Statins, which act as hydroxylmethyl glutaryl coenzyme A reductase
inhibitors, have been studied in patients with schizophrenia. A meta-analysis of 6 RCT,
totalizing 169 patients using statins as adjunctive therapy, found a significant
improvement for negative and positive symptoms. <sup><xref rid="ref55" ref-type="bibr">55</xref></sup>
Hypotheses underlying these effects concern anti-inflammatory properties,
interactions with P-glycoprotein substrates, or neuroprotective effects through
N-methyl-D-aspartate receptor upregulation and increase of muscarinic receptor binding.
In a large observational study, a reduction of self-harm has been observed. The authors
checked the files of 142 691 patients diagnosed with bipolar disorder, schizophrenia, or
nonaffective psychosis, and found a reduction in psychiatric hospitalization rates in
patients receiving statins, L-type calcium channel antagonists or biguanides such as
metformin. <sup><xref rid="ref56" ref-type="bibr">56</xref></sup>
&#x02029; </p></sec><sec><title>Thyroid hormones&#x02029;</title><p>
While there is no evidence that triiodothyronine (T3) alone is a useful
antidepressant, it is recommended as adjunctive medication for the treatment of
resistant depression. <sup><xref rid="ref57" ref-type="bibr">57</xref></sup>
, <sup><xref rid="ref58" ref-type="bibr">58</xref></sup>
Evidence for its efficacy comes mainly from its association with tricyclic
antidepressants or selective serotonin reuptake inhibitors (SSRIs). <sup><xref rid="ref59" ref-type="bibr">59</xref></sup>
Using thyroid hormones in bipolar depression is also being discussed, but
with less evidence. <sup><xref rid="ref60" ref-type="bibr">60</xref></sup>
&#x02029; </p></sec><sec><title>Outlook and conclusions&#x02029;</title><p>
The prescription of non-PMs in psychiatric disorders indicates that the
future of psychiatric treatment is not based solely on PMs. When favorable results with
a non-PM in a purely psychiatric indication are confirmed, the non-PM, after a period of
off-label use, is included in official guidelines <italic>(Table I)</italic>
and eventually registered by the FDA or other agencies. Each guideline
uses its own evaluation of evidence with less or more requirements. Usually, level 1
evidence corresponds to high-quality meta-analysis, level 2 to high-quality double-blind
RCT, level 3 to other studies, and level 4 to expert opinions.&#x02029; </p><p>
The hormone T3 is recommended as a second-line adjunctive medication in
treatment-resistant depression with a level 2 evidence while there already is level 1
evidence for ketamine perfusion which was still considered as experimental in some
guidelines for depression. <sup><xref rid="ref58" ref-type="bibr">58</xref></sup>
Pramipexole, intravenous ketamine, NAC, and T3 are considered as
third-line adjunctive treatment in bipolar depression, with level 3 evidence. <sup><xref rid="ref45" ref-type="bibr">45</xref></sup>
It is noteworthy to underline that a low level of evidence, such as a
level 3, does not necessarily mean lower efficacy or less tolerability, but can also
highlight a lack of studies, in number and in quality. It is the case of gabapentin
which is listed as first-line treatment in anxiety symptoms among bipolar patients,
despite only level 3 evidence. <sup><xref rid="ref61" ref-type="bibr">61</xref></sup>
The &#x003b2;-blocker propranolol is not recommended in anxiety guidelines,
because available data overall is against it for now. <sup><xref rid="ref62" ref-type="bibr">62</xref></sup>
Propranolol has been evaluated in many studies that do not reach expected
quality level; there are few RCTs and most of them concern panic attacks and
agoraphobia, for which a meta-analysis was not conclusive. <sup><xref rid="ref39" ref-type="bibr">39</xref></sup>
&#x02029; </p><p>
Evidence-based medicine is intrinsically limited by availability of data.
The example of lithium as a first choice in bipolar disorder is illustrative since this
undisputed reference drug for bipolar disorder only has level 2 evidence in bipolar
depression. Tamoxifen has level 2 evidence for treating acute mania, but with safety
concerns and little clinical experience <sup><xref rid="ref63" ref-type="bibr">63</xref></sup>
; therefore, contrarily to lithium, it cannot be advised as first-line
treatment. Concerning NSAIDs, a meta-analysis found positive results in depression,
which would correspond at least to level 2 evidence; however, there are limitations due
to the possibility of bias and to the heterogeneity of available studies. Moreover, the
use of NSAIDs in psychiatry needs an extensive appreciation of safety concerns, notably
about infectious risk. <sup><xref rid="ref64" ref-type="bibr">64</xref></sup>
&#x02029; </p><p>
Guidelines are a good summary of what is rather well established at a given
moment. But there are delays between the discovery of potential beneficial effects of a
molecule in a neuropsychiatric disorder and their validation with the inclusion of the
molecule in guidelines. Indeed, it takes time to finance and then perform quality
studies, the results of which finally get included into guidelines. So-called
preliminary data can sometimes remain a long time without confirmation, either positive
or negative. So, with several non-PMs, such as bumetanide, minocycline, and rifampicin,
as well as NSAIDs and SAMe, further trials are needed to establish their usefulness in
psychiatric treatment.&#x02029; </p><p>
These delays can be acceptable when other effective medications are
available, but they can be distressing to patients and therapists for disorders with no
known treatment. Considering the case of AD, current guidelines recommend at least a try
with cholinesterase inhibitors or NMDA antagonists, since there is no better
alternative. <sup><xref rid="ref65" ref-type="bibr">65</xref></sup>
This encourages exploration of new drugs and it will be important to
establish how much NSAIDs, rifampicin, or doxycycline really protect from AD or slow its
evolution. The same is true for preventing the development of PTSD, with very few data
available except rare but encouraging results for propranolol and hydrocortisone, which
administered shortly after a trauma, favorably influence memory retrieval. <sup><xref rid="ref66" ref-type="bibr">66</xref></sup>
, <sup><xref rid="ref67" ref-type="bibr">67</xref></sup>
Propranolol, (but not hydrocortisone), has been listed in a guideline as
an option to prevent the emergence of post-traumatic symptoms. <sup><xref rid="ref68" ref-type="bibr">68</xref></sup>
&#x02029; </p><p>
While the primary focus of our review is on the potential role of several
non-PMs on the evolution of psychiatric disorders, there are two other issues pertaining
to the relevance of medical treatments to psychiatry, first, the improvement of
psychiatric symptoms by treating non-psychiatric diseases, and, second, the prevention
of neuropsychiatric syndromes by treating or preventing non-psychiatric diseases.
Unfortunately, there are very few studies aimed at these clinically relevant questions.&#x02029; </p><p>
As for the first issue, many physical diseases or disorders such as
auto-immune diseases (lupus erythematosus, autoimmune encephalitis, etc), endocrine
diseases, Parkinson disease and other neurological diseases, intoxications, metabolic
diseases, infections, fever, dehydration, and many other situations induce psychiatric
symptoms. Depending on their severity, these situations could be treated without PMs,
ie, by improving the physical condition. Trials comparing psychiatric outcomes in non-PM
groups with non-PM plus PM groups are lacking.&#x02029; </p><p>
As to the second issue, which is relevant to psychiatric epidemiology, the
question raised is whether treatment or prevention of given non-psychiatric diseases
might delay or suppress the occurrence of neuropsychiatric syndromes: how do early
interventions delay or prevent the physical disease and how could this prevent
psychiatric complications? Examples are that the early detection of hypertension may
reduce dementia prevalence. <sup><xref rid="ref69" ref-type="bibr">69</xref></sup>
- <sup><xref rid="ref71" ref-type="bibr">71</xref></sup>
Cardiovascular prevention based on known risk factors has potential
beneficial effects on the incidence of psychiatric disorders. An epidemiological study
did show a reduction of psychiatric hospitalization among patients receiving statins,
L-type calcium channel antagonists, or biguanides. <sup><xref rid="ref56" ref-type="bibr">56</xref></sup>
But a causal link cannot be asserted. Were the findings a direct or
indirect effect of the non-PMs on the psychiatric disorders? Do these non-PMs have clear
psychotropic properties? And if so, what are these properties? Psychiatric patients
often receive less care than they should; so, by receiving cardiovascular treatments,
were these patients more exposed to also receiving treatment for psychiatric symptoms?
There are also questions about the association between cardiovascular and psychiatric
disorders and about how treating one may affect the other. Diabetes mellitus is highly
associated with depression. <sup><xref rid="ref72" ref-type="bibr">72</xref></sup>
If untreated, it leads to cardiovascular complications, themselves
associated with mood disorders or dementia. Obesity, the major risk factor for
cardiovascular disorders, and a source of stigmatization among young people, shows a
reciprocal link with depression. <sup><xref rid="ref73" ref-type="bibr">73</xref></sup>
, <sup><xref rid="ref74" ref-type="bibr">74</xref></sup>
Vaccination is among the best illustrations of how psychiatric symptoms
can be prevented by internal medicine interventions. Vaccines protect against many
infections that affect brain functions: tick-borne diseases, viral encephalitis, etc. In
some cases, the relation between psychiatric disorders and nonpsychiatric diseases is
reciprocal. For example, treatment of tobacco addiction decreases the prevalence of
COPD, and a reduced prevalence of this severe physical disease lessens its psychiatric
complications, notably depression.&#x02029; </p><p>
We reviewed several non-PMs that already have or that could have a role in
the practice of psychiatry. There is sufficient evidence for some non-PMs to be
recommended in psychiatric guidelines, indicating that the pharmacological treatment of
psychiatric disorders does not only rely on PMs. However, the lack of high-quality data
remains the main issue for most of the indications of non-PMs in neuropsychiatric
disorders.&#x02029; </p><p>
<table-wrap orientation="portrait" id="d35e529" position="float"><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1"> Drug&#x02028; </td><td rowspan="1" colspan="1"> Drug class&#x02028; </td><td rowspan="1" colspan="1"> Official &#x02028;indication </td><td rowspan="1" colspan="1"> Psychiatric &#x02028;disorder </td><td rowspan="1" colspan="1"> Recommendation &#x02028;in psychiatry* </td></tr></thead><tbody><tr><td rowspan="1" colspan="1"> 5-HTP </td><td rowspan="1" colspan="1"> Amino acid </td><td rowspan="1" colspan="1"> None </td><td rowspan="1" colspan="1"> Depression </td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"> Amantadine </td><td rowspan="1" colspan="1"> NMDA receptor &#x02028;antagonist </td><td rowspan="1" colspan="1"> Parkinsonian symptoms, influenza treatment and prophylaxis </td><td rowspan="1" colspan="1"> Alzheimer disease </td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"> Bumetanide </td><td rowspan="1" colspan="1"> Loop diuretic </td><td rowspan="1" colspan="1"> Swelling </td><td rowspan="1" colspan="1"> Autism spectrum disorders, schizophrenia </td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"> Clonidine </td><td rowspan="1" colspan="1"> Central &#x02028;a-2 agonist </td><td rowspan="1" colspan="1"> High blood pressure, cancer pain, ADHD in pediatric population </td><td rowspan="1" colspan="1"> ADHD&#x02028;Smoking cessation </td><td rowspan="1" colspan="1"> Recommended in ADHD if no response to other treatments and after advice
from tertiary ADHD service14&#x02029; Recommended as second-&#x02028;line
treatment in smoking cessation16 </td></tr><tr><td rowspan="1" colspan="1"> Gabapentine </td><td rowspan="1" colspan="1"> Agonist GABA </td><td rowspan="1" colspan="1"> Epilepsy, neuropathic pain </td><td rowspan="1" colspan="1"> Anxiety disorder, &#x02028;bipolar disorder </td><td rowspan="1" colspan="1"> Yes as third-line treatment in panic disorder, second-line in social
anxiety disorder, and third-line adjunctive therapy in PTSD62&#x02029; As
first-line treatment in anxiety disorders associated with bipolar
disorder61&#x02029; In maintenance therapy in &#x02028;bipolar disorder45 </td></tr><tr><td rowspan="1" colspan="1"> Guanfacine </td><td rowspan="1" colspan="1"> Central &#x02028;a-2 agonist </td><td rowspan="1" colspan="1"> High blood pressure,&#x02028;ADHD in pediatric population </td><td rowspan="1" colspan="1"> ADHD </td><td rowspan="1" colspan="1"> Recommended if no response to other treatments and after advice from
tertiary ADHD service14 </td></tr><tr><td rowspan="1" colspan="1"> Ketamine in &#x02028;perfusion** </td><td rowspan="1" colspan="1"> NMDA receptor antagonist </td><td rowspan="1" colspan="1"> Anesthesia </td><td rowspan="1" colspan="1"> Unipolar and bipolar &#x02028;depression </td><td rowspan="1" colspan="1"> As third-line adjunctive treatment in bipolar depression45 </td></tr><tr><td rowspan="1" colspan="1"> Minocycline </td><td rowspan="1" colspan="1"> Antibiotics </td><td rowspan="1" colspan="1"> Infections, acne </td><td rowspan="1" colspan="1"> Depression </td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"> NAC </td><td rowspan="1" colspan="1"> Amino acid </td><td rowspan="1" colspan="1"> Mucous secretions in broncho-pulmonary disorders, antidote for
paracetamol overdose </td><td rowspan="1" colspan="1"> Unipolar and bipolar depression, &#x02028;schizophrenia </td><td rowspan="1" colspan="1"> As third-line adjunctive &#x02028;treatment in bipolar
&#x02028;depression45 </td></tr><tr><td rowspan="1" colspan="1"> NSAIDs </td><td rowspan="1" colspan="1"> Anti-inflammatory </td><td rowspan="1" colspan="1"> Pain, fever </td><td rowspan="1" colspan="1"> Mood disorders </td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"> Acetylsalicylic acid </td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"> Cardiovascular &#x02028;prophylaxis </td><td rowspan="1" colspan="1"> Schizophrenia&#x02028;Depression </td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"> Pramipexole </td><td rowspan="1" colspan="1"> Antiparkinsonian </td><td rowspan="1" colspan="1"> Parkinsonian symptoms, restless legs syndrome </td><td rowspan="1" colspan="1"> Unipolar and bipolar depression </td><td rowspan="1" colspan="1"> As third-line adjunctive treatment in bipolar depression45 </td></tr><tr><td rowspan="1" colspan="1"> Propranolol </td><td rowspan="1" colspan="1"> &#x003b2;-blockers </td><td rowspan="1" colspan="1"> High blood pressure, angina pectoris, atrial fibrillation, migraine,
essential tremor </td><td rowspan="1" colspan="1"> Anxiety disorders, PTSD prevention </td><td rowspan="1" colspan="1"> Not recommended in GAD, SAD, or PD62&#x02028;Can be discussed in
&#x02028;prevention of post-traumatic symptoms68 </td></tr><tr><td rowspan="1" colspan="1"> Rifampicin </td><td rowspan="1" colspan="1"> Antibiotics </td><td rowspan="1" colspan="1"> Infections </td><td rowspan="1" colspan="1"> Depression </td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"> S-adenosyl-L methionine </td><td rowspan="1" colspan="1"> Substrate in &#x02028;different metabolic reactions </td><td rowspan="1" colspan="1"> None </td><td rowspan="1" colspan="1"> Depression </td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"> Statins </td><td rowspan="1" colspan="1"> Hypolipidemic drugs </td><td rowspan="1" colspan="1"> Hypercholesterolemia, hypertriglyceridemia </td><td rowspan="1" colspan="1"> Schizophrenia </td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"> Tamoxifen </td><td rowspan="1" colspan="1"> Chemotherapy </td><td rowspan="1" colspan="1"> Breast cancer </td><td rowspan="1" colspan="1"> Acute mania </td><td rowspan="1" colspan="1"> As third-line treatment in acute mania45 </td></tr><tr><td rowspan="1" colspan="1"> T3 </td><td rowspan="1" colspan="1"> Thyroid hormone </td><td rowspan="1" colspan="1"> Hypothyroidism </td><td rowspan="1" colspan="1"> Unipolar and bipolar depression </td><td rowspan="1" colspan="1"> As second-line adjunctive &#x02028;medication in treatment
&#x02028;resistant depression58&#x02028;As third-line adjunctive treatment
in bipolar depression45 </td></tr></tbody></table></table-wrap>
</p></sec></body><back><ack><p>The authors have no conflicts of interest.</p></ack><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berk</surname><given-names>M,</given-names></name><name><surname>Dean</surname><given-names>O,</given-names></name><name><surname>Drexhage</surname><given-names>H,</given-names></name><name><surname>et al.</surname><given-names/></name></person-group><article-title>Aspirin: a review of its neurobiological properties and therapeutic
potential for mental illness.</article-title><source><italic>BMC Med.</italic></source><year>2013</year><fpage>11</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">23324495</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendlewicz</surname><given-names>J,</given-names></name><name><surname>Kriwin</surname><given-names>P,</given-names></name><name><surname>Oswald</surname><given-names>P,</given-names></name><name><surname>Souery </surname><given-names>D,</given-names></name><name><surname>Alboni</surname><given-names>S,</given-names></name><name><surname>Brunello</surname><given-names>N.</given-names></name></person-group><article-title>Shortened onset of action of antidepressants in major depression using
acetylsalicylic acid augmentation: a pilot open-label study.</article-title><source><italic>Int Clin Psychopharmacol.</italic></source><year>2006</year><volume>21</volume><issue>4</issue><fpage>227231</fpage></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savitz</surname><given-names>J,</given-names></name><name><surname>Preskorn</surname><given-names>S,</given-names></name><name><surname>Teague</surname><given-names>TK,</given-names></name><name><surname>Drevets</surname><given-names>D,</given-names></name><name><surname>Yates</surname><given-names>W,</given-names></name><name><surname>Drevets</surname><given-names>W.</given-names></name></person-group><article-title>Minocycline and aspirin in the treatment of bipolar depression: a
protocol for a proof-of-concept, randomised, double-blind, placebo-controlled, 2x2
clinical trial.</article-title><source><italic>BMJ Open.</italic></source><year>2012</year><volume>2</volume><issue>1</issue><fpage>e000643</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2011-000643.</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenblat</surname><given-names>JD,</given-names></name><name><surname>Kakar</surname><given-names>R,</given-names></name><name><surname>Berk</surname><given-names>M,</given-names></name><name><surname>et al.</surname><given-names/></name></person-group><article-title>Anti-inflammatory agents in the treatment of bipolar depression: a
systematic review and meta-analysis.</article-title><source><italic>Bipolar Disord.</italic></source><year>2016</year><volume>18</volume><issue>2</issue><fpage>89</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">26990051</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>K&#x000f6;hler</surname><given-names>O,</given-names></name><name><surname>Benros</surname><given-names>ME,</given-names></name><name><surname>Nordentoft</surname><given-names>M,</given-names></name><name><surname>et al.</surname><given-names/></name></person-group><article-title>Effect of anti-inflammatory treatment on depression, depressive
symptoms, and adverse effects: a systematic review and meta-analysis of randomized
clinical trials. 71</article-title><source><italic>JAMA Psychiatry.</italic></source><year>2014</year><issue>12</issue><fpage>1381</fpage><lpage>1391</lpage><pub-id pub-id-type="pmid">25322082</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Husain</surname><given-names>MI,</given-names></name><name><surname>Strawbridge</surname><given-names>R,</given-names></name><name><surname>Stokes</surname><given-names>PR,</given-names></name><name><surname>Young</surname><given-names>AH.</given-names></name></person-group><article-title>Anti-inflammatory treatments for mood disorders: Systematic review and
meta-analysis.</article-title><source><italic>J Psychopharmacol.</italic></source><year>2017</year><volume>31</volume><issue>9</issue><fpage>11371148</fpage></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laan</surname><given-names>W,</given-names></name><name><surname>Grobbee</surname><given-names>DE,</given-names></name><name><surname>Selten</surname><given-names>JP,</given-names></name><name><surname>Heijnen</surname><given-names>CJ,</given-names></name><name><surname>Kahn</surname><given-names>RS,</given-names></name><name><surname>Burger</surname><given-names>H.</given-names></name></person-group><article-title>Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum
disorders: results from a randomized, double-blind, placebo-controlled
trial.</article-title><source><italic>J Clin Psychiatry.</italic></source><year>2010</year><volume>71</volume><issue>5</issue><fpage>520527</fpage></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deardorff</surname><given-names>WJ,</given-names></name><name><surname>Grossberg</surname><given-names>GT.</given-names></name></person-group><article-title>Targeting neuroinflammation in Alzheimer&#x02019;s disease: evidence for
NSAIDs and novel therapeutics.</article-title><source><italic>Exp Rev Neurother.</italic></source><year>2017</year><volume>17</volume><issue>1</issue><fpage>1732</fpage></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nevado-Holgado</surname><given-names>AJ,</given-names></name><name><surname>Lovestone</surname><given-names>S.</given-names></name></person-group><article-title>Determining the molecular pathways underlying the protective effect of
non-steroidal anti-inflammatory drugs for Alzheimer&#x02019;s disease: A bioinformatics
approach.</article-title><source><italic>Comput Struct Biotechnol J.</italic></source><year>2017</year><volume>15</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">27872687</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemonnier</surname><given-names>E,</given-names></name><name><surname>Villeneuve</surname><given-names>N,</given-names></name><name><surname>Sonie</surname><given-names>S,</given-names></name><name><surname>et al.</surname><given-names/></name></person-group><article-title>Effects of bumetanide on neurobehavioral function in children and
adolescents with autism spectrum disorders.</article-title><source><italic>Transl Psychiatry.</italic></source><year>2017</year><volume>7</volume><issue>3</issue><fpage>e1056</fpage><pub-id pub-id-type="doi">10.1038/tp.2017.10.</pub-id><pub-id pub-id-type="pmid">28291262</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemonnier</surname><given-names>E,</given-names></name><name><surname>Lazartigues</surname><given-names>A,</given-names></name><name><surname>Ben-Ari</surname><given-names>Y.</given-names></name></person-group><article-title>Treating schizophrenia with the diuretic bumetanide: a case
report.</article-title><source><italic>Clin Neuropharmacol.</italic></source><year>2016</year><volume>39</volume><issue>2</issue><fpage>115</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">26966887</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahmanzadeh</surname><given-names>R,</given-names></name><name><surname>Shahbazi</surname><given-names>A,</given-names></name><name><surname>Ardakani</surname><given-names>MK,</given-names></name><name><surname>Mehrabi</surname><given-names>S,</given-names></name><name><surname>Rahmanzade</surname><given-names>R,</given-names></name><name><surname>Joghateaei</surname><given-names>MT.</given-names></name></person-group><article-title>Lack of the effect of bumetanide, a selective NKCC1 inhibitor, in
patients with schizophrenia: a double-blind randomized trial.</article-title><source><italic>Psychiatry Clin Neurosci.</italic></source><year>2017</year><volume>71</volume><issue>1</issue><fpage>72</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">27800670</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lowry</surname><given-names>JA,</given-names></name><name><surname>Brown</surname><given-names>JT.</given-names></name></person-group><article-title>Significance of the imidazoline receptors in
toxicology.</article-title><source><italic>Clin Toxicol (Phila).</italic></source><year>2014 Jun</year><volume>52</volume><issue>5</issue><fpage>454</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">24666288</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><article-title>Attention deficit hyperactivity disorder : diagnosis and
management.</article-title><source><italic/></source><comment>Available at :</comment></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naguy</surname><given-names>A.</given-names></name></person-group><article-title>Clonidine use in psychiatry: panacea or panache.</article-title><source><italic>Pharmacology.</italic></source><year>2016</year><volume>98</volume><issue>1-2</issue><fpage>87</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">27161101</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiore</surname><given-names>MC,</given-names></name><name><surname>Ja&#x000e9;n</surname><given-names>CR,</given-names></name><name><surname>Baker</surname><given-names>TB,</given-names></name><name><surname>et al.</surname><given-names/></name></person-group><article-title>Treating tobacco use and dependence: 2008 update.</article-title><source><italic>Clinical Practice Guideline.</italic></source><year>2008</year></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kung</surname><given-names>S,</given-names></name><name><surname>Espinel</surname><given-names>Z,</given-names></name><name><surname>Lapid</surname><given-names>MI.</given-names></name></person-group><article-title>Treatment of nightmares with prazosin: a systematic
review.</article-title><source><italic>Mayo Clin Proc.</italic></source><year>2012</year><volume>87</volume><issue>9</issue><fpage>890</fpage><lpage>900</lpage><pub-id pub-id-type="pmid">22883741</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berlin</surname><given-names>RK,</given-names></name><name><surname>Butler</surname><given-names>PM,</given-names></name><name><surname>Perloff</surname><given-names>MD.</given-names></name></person-group><article-title>Gabapentin therapy in psychiatric disorders: a systematic
review.</article-title><source><italic>Prim Care Companion CNS Disord.</italic></source><year>2015</year><volume>17</volume><issue>5</issue><fpage>10.4088/PCC.15r01821</fpage><pub-id pub-id-type="doi">10.4088/PCC.15r01821.</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Culpepper</surname><given-names>L,</given-names></name><name><surname>Wingertzahn</surname><given-names>MA.</given-names></name></person-group><article-title>Over-the-counter agents for the treatment of occasional disturbed
sleep or transient insomnia: a systematic review of efficacy and
safety.</article-title><source><italic>Prim Care Companion CNS Disord.</italic></source><year>2015</year><volume>17</volume><issue>6</issue><fpage>10.4088</fpage><lpage>PCC.15r01798</lpage><pub-id pub-id-type="doi">10.4088/PCC.15r01798</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guaiana</surname><given-names>G,</given-names></name><name><surname>Barbui</surname><given-names>C,</given-names></name><name><surname>Cipriani</surname><given-names>A.</given-names></name></person-group><article-title>Hydroxyzine for generalised anxiety disorder.</article-title><source><italic>Cochrane Database Syst Rev.</italic></source><year>2010</year><volume>12</volume><fpage>CD006815</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD006815.pub2</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iadarola</surname><given-names>ND,</given-names></name><name><surname>Niciu</surname><given-names>MJ,</given-names></name><name><surname>Richards</surname><given-names>EM,</given-names></name><name><surname>et al.</surname><given-names/></name></person-group><article-title>Ketamine and other N-methyl-D-aspartate receptor antoagnonists in the
treatment of depression: a perspective review.</article-title><source><italic>Ther Adv Chronic Dis.</italic></source><year>2015</year><volume>6</volume><issue>3</issue><fpage>97</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">25954495</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><article-title>FDA approves new nasal spray medication for treatment-resistant
depression; available only at a certified doctor&#x02019;s office or
clinic.</article-title><source><italic/></source><comment>Available at:</comment></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kishi</surname><given-names>T,</given-names></name><name><surname>Matsunaga</surname><given-names>S,</given-names></name><name><surname>Oya</surname><given-names>K,</given-names></name><name><surname>Nomura</surname><given-names>I,</given-names></name><name><surname>Ikuta</surname><given-names>T,</given-names></name><name><surname>Iwata</surname><given-names>N.</given-names></name></person-group><article-title>Memantine for Alzheimer&#x02019;s disease: an updated systematic review and
meta-analysis.</article-title><source><italic>J Alzheimers Dis.</italic></source><year>2017</year><volume>60</volume><issue>2</issue><fpage>401</fpage><lpage>425</lpage><pub-id pub-id-type="pmid">28922160</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garido-Mesa</surname><given-names>N,</given-names></name><name><surname>Zarzuelo</surname><given-names>A,</given-names></name><name><surname>Galvez</surname><given-names>J.</given-names></name></person-group><article-title>Minocycline: far beyond an antibiotic.</article-title><source><italic>Br J Pharmacol.</italic></source><year>2013</year><volume>169</volume><issue>2</issue><fpage>337</fpage><lpage>352</lpage><pub-id pub-id-type="pmid">23441623</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenblat</surname><given-names>JD,</given-names></name><name><surname>McIntyre</surname><given-names>RS.</given-names></name></person-group><article-title>Efficacy and tolerability of minocycline for depression: a systematic
review and meta-analysis of clinical trials.</article-title><source><italic>J Affect Disord.</italic></source><year>2018</year><volume>227</volume><fpage>219</fpage><lpage>225</lpage><pub-id pub-id-type="pmid">29102836</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savitz</surname><given-names>JB,</given-names></name><name><surname>Teague</surname><given-names>TK,</given-names></name><name><surname>Misaki</surname><given-names>M,</given-names></name><name><surname>et al.</surname><given-names/></name></person-group><article-title>Treatment of bipolar depression with minocycline and/or aspirin: an
adaptive, 2&#x000d7;2 double-blind, randomized, placebo-controlled, phase IIA clinical
trial.</article-title><source><italic>Transl Psychiatry.</italic></source><year>2018</year><volume>8</volume><issue>1</issue><fpage>27</fpage><pub-id pub-id-type="doi">10.1038/s41398-017-0073-7.</pub-id><pub-id pub-id-type="pmid">29362444</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murrough</surname><given-names>JW,</given-names></name><name><surname>Huryk</surname><given-names>KM,</given-names></name><name><surname>Mao</surname><given-names>X,</given-names></name><name><surname>et al.</surname><given-names/></name></person-group><article-title>A pilot study of minocycline for the treatment of bipolar depression:
effects on cortical glutathione and oxidative stress in vivo.</article-title><source><italic>J Affect Disord.</italic></source><year>2018</year><volume>1</volume><issue>230</issue><fpage>56</fpage><lpage>64</lpage></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deaking</surname><given-names>B,</given-names></name><name><surname>Suckling</surname><given-names>J,</given-names></name><name><surname>Barnes</surname><given-names>TRE,</given-names></name><name><surname>et al.</surname><given-names/></name></person-group><article-title>The benefit of minocycline on negative symptoms of schizophrenia in
patients with recent-onset psychosis (BeneMin): a randomized, double-blind,
placebo-controlled trial.</article-title><source><italic>Lancet Psychiatry.</italic></source><year>2018</year><volume>5</volume><issue>11</issue><fpage>885</fpage><lpage>894</lpage><pub-id pub-id-type="pmid">30322824</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levkovitz</surname><given-names>Y,</given-names></name><name><surname>Mendlovich</surname><given-names>S,</given-names></name><name><surname>Riwkes</surname><given-names>S,</given-names></name><name><surname>et al.</surname><given-names/></name></person-group><article-title>A double-blind, randomized study of minocycline for the treatment of
negative and cognitive symptoms in early-phase schizophrenia.</article-title><source><italic>J Clin Psychiatry.</italic></source><year>2010</year><volume>71</volume><issue>2</issue><fpage>138</fpage><lpage>148</lpage><pub-id pub-id-type="pmid">19895780</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiang</surname><given-names>YQ,</given-names></name><name><surname>Zheng</surname><given-names>W,</given-names></name><name><surname>Wang</surname><given-names>SB,</given-names></name><name><surname>et al.</surname><given-names/></name></person-group><article-title>Adjunctive minocycline for schizophrenia: a meta-analysis of
randomized controlled trials.</article-title><source><italic>Eur Neuropsychopharmacol.</italic></source><year>2017</year><volume>27</volume><issue>1</issue><fpage>8</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">27919523</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Umeda</surname><given-names>T,</given-names></name><name><surname>Ono</surname><given-names>K,</given-names></name><name><surname>Sakai</surname><given-names>A,</given-names></name><name><surname>et al.</surname><given-names/></name></person-group><article-title>Rifampicin is a candidate preventive medicine against amyloid-beta and
tau oligomers.</article-title><source><italic>Brain.</italic></source><year>2016</year><volume>139</volume><fpage>1568</fpage><lpage>1586</lpage><pub-id pub-id-type="pmid">27020329</pub-id></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yulug</surname><given-names>B,</given-names></name><name><surname>Hanoglu</surname><given-names>L,</given-names></name><name><surname>Ozansov</surname><given-names>M,</given-names></name><name><surname>et al.</surname><given-names/></name></person-group><article-title>Therapeutic role of rifampicin in Alzheimer&#x02019;s disease.</article-title><source><italic>Psychiatry Clin Neurosci.</italic></source><year>2018</year><volume>72</volume><issue>3</issue><fpage>152</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">29315976</pub-id></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loeb</surname><given-names>MB,</given-names></name><name><surname>Molloy</surname><given-names>DW,</given-names></name><name><surname>Smieja</surname><given-names>M,</given-names></name><name><surname>et al.</surname><given-names/></name></person-group><article-title>A randomized, controlled trial of doxycycline and rifampin for
patients with Alzheimer&#x02019;s disease.</article-title><source><italic>J Am Geriatr Soc.</italic></source><year>2004</year><volume>52</volume><fpage>381</fpage><lpage>387</lpage><pub-id pub-id-type="pmid">14962152</pub-id></element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iizuka</surname><given-names>T,</given-names></name><name><surname>Morimoto</surname><given-names>K,</given-names></name><name><surname>Sasaki</surname><given-names>Y,</given-names></name><name><surname>et al.</surname><given-names/></name></person-group><article-title>Preventive effect of rifampicin on Alzheimer disease needs at least
450 mg daily for 1 year: an FDG-PET follow-up study.</article-title><source><italic>Dement Geriatr Cogn Dis Extra.</italic></source><year>2017</year><volume>7</volume><fpage>201</fpage><lpage>214</lpage></element-citation></ref><ref id="ref35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molloy</surname><given-names>DW,</given-names></name><name><surname>Standish</surname><given-names>TI,</given-names></name><name><surname>Zhou</surname><given-names>Q,</given-names></name><name><surname>Guyatt</surname><given-names>G,</given-names></name><name><surname>DARAD Study group.</surname><given-names/></name></person-group><article-title>A multicenter, blinded, randomized, factorial controlled trial of
doxycycline and rifampin for treatment of Alzheimer&#x02019;s disease: The DARAD
trial.</article-title><source><italic>Int J Geriatr Psychiatry.</italic></source><year>2013</year><volume>28</volume><fpage>463</fpage><lpage>470</lpage><pub-id pub-id-type="pmid">22718435</pub-id></element-citation></ref><ref id="ref36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lizuka</surname><given-names>T,</given-names></name><name><surname>Morimoto</surname><given-names>K,</given-names></name><name><surname>Sasaki</surname><given-names>Y,</given-names></name><name><surname>et al.</surname><given-names/></name></person-group><article-title>Preventive effect of rifampicin on Alzheimer disease needs at least
450 mg daily for 1 year: an FDG &#x02013;PET follow-up study.</article-title><source><italic>Dement Geriatr Cogn Dis Extra.</italic></source><year>2017</year><volume>7</volume><issue>2</issue><fpage>204</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">28690634</pub-id></element-citation></ref><ref id="ref37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname><given-names>TC,</given-names></name><name><surname>Brown</surname><given-names>IR.</given-names></name></person-group><article-title>Cysteamine in combination with&#x000a0;N-acetylcysteine prevents
acetaminophen-induced hepatotoxicity.</article-title><source><italic>Can J Physiol Pharmacol.</italic></source><year>1992</year><volume>70</volume><issue>1</issue><fpage>20</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">1581851</pub-id></element-citation></ref><ref id="ref38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minarini</surname><given-names>A,</given-names></name><name><surname>Ferrari</surname><given-names>S,</given-names></name><name><surname>Galleti</surname><given-names>M,</given-names></name><name><surname>et al.</surname><given-names/></name></person-group><article-title>N-acetylcysteine in the treatment of psychiatric disorders: current
status and future prospects.</article-title><source><italic>Expert Opin Drug Metab Toxicol.</italic></source><year>2017</year><volume>13</volume><issue>3</issue><fpage>279</fpage><lpage>292</lpage><pub-id pub-id-type="pmid">27766914</pub-id></element-citation></ref><ref id="ref39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deepmala,</surname><given-names>J,</given-names></name><name><surname>Slattery</surname><given-names>J,</given-names></name><name><surname>Kumar</surname><given-names>N,</given-names></name><name><surname>et al.</surname><given-names/></name></person-group><article-title>Clinical trials of N-acetylcysteine in psychiatry and neurology: a
systematic review.</article-title><source><italic>Neurosci Biobehav Rev.</italic></source><year>2015</year><volume>55</volume><fpage>294</fpage><lpage>321</lpage><pub-id pub-id-type="pmid">25957927</pub-id></element-citation></ref><ref id="ref40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhen</surname><given-names>W,</given-names></name><name><surname>Zhang</surname><given-names>QE,</given-names></name><name><surname>Cai</surname><given-names>DB,</given-names></name><name><surname>et al.</surname><given-names/></name></person-group><article-title>N-acetylcysteine for major mental disorders: a systematic review and
meta-analysis of randomized controlled trials.</article-title><source><italic>Acta Psychiatr Scand.</italic></source><year>2018</year><volume>137</volume><issue>5</issue><fpage>391</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">29457216</pub-id></element-citation></ref><ref id="ref41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>A,</given-names></name><name><surname>Gerbarg</surname><given-names>P,</given-names></name><name><surname>Bottiglieri</surname><given-names>T,</given-names></name><name><surname>et al.</surname><given-names/></name></person-group><article-title>S-Adenosylmethionine (SAMe) for neuropsychiatric disorders: a
clinician-oriented review of research.</article-title><source><italic>J Clin Psychiatry. </italic></source><year>2017</year><volume>78</volume><issue>6</issue><fpage>e656</fpage><lpage>e667</lpage><pub-id pub-id-type="pmid">28682528</pub-id></element-citation></ref><ref id="ref42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>K,</given-names></name><name><surname>Turner</surname><given-names>J,</given-names></name><name><surname>Del Mar</surname><given-names>C.</given-names></name></person-group><article-title>Tryptophan and 5-hydroxytryptophan for depression.</article-title><source><italic>Cochrane Database Syst Rev.</italic></source><year>2002</year><issue>1</issue><fpage>CD003198</fpage><pub-id pub-id-type="pmid">11869656</pub-id></element-citation></ref><ref id="ref43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hori</surname><given-names>H,</given-names></name><name><surname>Kunugi</surname><given-names>H.</given-names></name></person-group><article-title>Dopamine agonist-&#x02028;responsive depression.</article-title><source><italic>Psychogeriatrics.</italic></source><year>2016</year><volume>13</volume><issue>3</issue><fpage>89</fpage><lpage>95</lpage></element-citation></ref><ref id="ref44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corrigan</surname><given-names>MH,</given-names></name><name><surname>Denahan</surname><given-names>AQ,</given-names></name><name><surname>Wright</surname><given-names>CE,</given-names></name><name><surname>Ragual</surname><given-names>RJ,</given-names></name><name><surname>Evans</surname><given-names>DL.</given-names></name></person-group><article-title>Comparison of pramipexole, fluoxetine, and placebo in patients with
major depression.</article-title><source><italic>Depress Anxiety.</italic></source><year>2000</year><volume>11</volume><issue>2</issue><fpage>58</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">10812530</pub-id></element-citation></ref><ref id="ref45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yatham</surname><given-names>LN,</given-names></name><name><surname>Kennedy</surname><given-names>SH,</given-names></name><name><surname>Parikh</surname><given-names>SV,</given-names></name><name><surname>Schaffer</surname><given-names>A,</given-names></name><name><surname>Bond</surname><given-names>DJ,</given-names></name><name><surname>Frey</surname><given-names>BN.</given-names></name></person-group><article-title>Canadian Network for mood and anxiety treatments (CANMAT) and
International Society for Bipolar Disorders (ISBD) 2018 guidelines for the
management of patients with bipolar disorder.</article-title><source><italic>Bipolar Disord.</italic></source><year>2018</year><volume>20</volume><issue>2</issue><fpage>97</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">29536616</pub-id></element-citation></ref><ref id="ref46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shingu</surname><given-names>K,</given-names></name><name><surname>Kawai</surname><given-names>I,</given-names></name><name><surname>Yamada</surname><given-names>K.</given-names></name></person-group><article-title>Thee cases of unipolar delusional depression responsive to
L-dopa.</article-title><source><italic>Folia Psychiatr Neurol Jpn.</italic></source><year>1979</year><volume>33</volume><issue>4</issue><fpage>511</fpage><lpage>515</lpage><pub-id pub-id-type="pmid">535833</pub-id></element-citation></ref><ref id="ref47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koella</surname><given-names>WP.</given-names></name></person-group><article-title>CNS-related (side-)effects of beta blockers with special reference to
mechanisms of action.</article-title><source><italic>Eur J Clin Pharmacol.</italic></source><year>1985</year><volume>28</volume><issue>Suppl</issue><fpage>55</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">2865151</pub-id></element-citation></ref><ref id="ref48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cruickshank</surname><given-names>JM.</given-names></name></person-group><article-title>The clinical importance of cardioselectivity and lipophilicity in beta
blockers.</article-title><source><italic>Am Heart J.</italic></source><year>1980</year><volume>100</volume><fpage>160</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">6105819</pub-id></element-citation></ref><ref id="ref49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravaris</surname><given-names>CL,</given-names></name><name><surname>Friedman</surname><given-names>MJ,</given-names></name><name><surname>Hauri</surname><given-names>PJ,</given-names></name><name><surname>McHugo</surname><given-names>GJ.</given-names></name></person-group><article-title>A controlled study of alprazolam and propranolol in panic-disordered
and agoraphobic outpatients.</article-title><source><italic>J Clin Psychopharmacol.</italic></source><year>1991</year><volume>11</volume><issue>6</issue><fpage>344</fpage><lpage>350</lpage><pub-id pub-id-type="pmid">1770152</pub-id></element-citation></ref><ref id="ref50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steenen</surname><given-names>SA,</given-names></name><name><surname>van Wijk</surname><given-names>AJ,</given-names></name><name><surname>van der Heijden </surname><given-names>GJ,</given-names></name><name><surname>van Westrhenen</surname><given-names>R,</given-names></name><name><surname>de Lange</surname><given-names>G,</given-names></name><name><surname>de Jongh</surname><given-names>A.</given-names></name></person-group><article-title>Propranolol for the treatment of anxiety disorders: systematic review
and meta-analysis.</article-title><source><italic>J Psychopharmacol.</italic></source><year>2016</year><volume>30</volume><issue>2</issue><fpage>128</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">26487439</pub-id></element-citation></ref><ref id="ref51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lonergan</surname><given-names>MH,</given-names></name><name><surname>Olivera-Figueroa</surname><given-names>LA,</given-names></name><name><surname>Pitman</surname><given-names>RK,</given-names></name><name><surname>Brunet</surname><given-names>A.</given-names></name></person-group><article-title>Propranolol&#x02019;s effects on the consolidation and reconsolidation of
long-term emotional memory in healthy participants: a
meta-analysis.</article-title><source><italic>J Psychiatry Neurosci.</italic></source><year>2013</year><volume>33</volume><issue>4</issue><fpage>222</fpage><lpage>231</lpage></element-citation></ref><ref id="ref52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burbiel</surname><given-names>JC.</given-names></name></person-group><article-title>Primary prevention of posttraumatic stress disorder: drugs and
implications.</article-title><source><italic>Mil Med Res.</italic></source><year>2015</year><volume>2</volume><fpage>24</fpage><pub-id pub-id-type="doi">10.1186/s40779-015-0053-2.</pub-id><pub-id pub-id-type="pmid">26504586</pub-id></element-citation></ref><ref id="ref53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunet</surname><given-names>A,</given-names></name><name><surname>Orr</surname><given-names>SP,</given-names></name><name><surname>Tremblay</surname><given-names>H,</given-names></name><name><surname>Robertson </surname><given-names>K,</given-names></name><name><surname>Nader</surname><given-names>K,</given-names></name><name><surname>Pitman</surname><given-names>RK.</given-names></name></person-group><article-title>Effect of post-retrieval propranolol on psychophysiologic responding
during subsequent script-driver traumatic imagery in post-traumatic stress
disorder.</article-title><source><italic>J Psychiatr Res.</italic></source><year>2008</year><volume>42</volume><issue>6</issue><fpage>503</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">17588604</pub-id></element-citation></ref><ref id="ref54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunet</surname><given-names>A,</given-names></name><name><surname>Saumer</surname><given-names>D,</given-names></name><name><surname>Lia</surname><given-names>A,</given-names></name><name><surname>Streiner</surname><given-names>Dl,</given-names></name><name><surname>Tremblay</surname><given-names>J,</given-names></name><name><surname>Pitman</surname><given-names>RK.</given-names></name></person-group><article-title>Reduction of PTSD symptoms with pre-reactivation propranolol therapy&#x000a0;:
a randomized controlled trial.</article-title><source><italic>Am J Psychiatry.</italic></source><year>2018</year><volume>175</volume><issue>5</issue><fpage>427</fpage><lpage>433</lpage><pub-id pub-id-type="pmid">29325446</pub-id></element-citation></ref><ref id="ref55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>H,</given-names></name><name><surname>Li</surname><given-names>R,</given-names></name><name><surname>Yan</surname><given-names>R,</given-names></name><name><surname>et al.</surname><given-names/></name></person-group><article-title>Adjunctive therapy with statins in schizophrenia patients : a
meta-analysis and implications.</article-title><source><italic>Psychiatry Res.</italic></source><year>2018</year><volume>262</volume><fpage>84</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">29427912</pub-id></element-citation></ref><ref id="ref56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayes</surname><given-names>JF,</given-names></name><name><surname>lundi</surname><given-names>A,</given-names></name><name><surname>Wicks</surname><given-names>S,</given-names></name><name><surname>et al.</surname><given-names/></name></person-group><article-title>Association of hydroxylmethyl glutaryl coenzymes A reductase
inhibitors, L-type calcium channel antagonists, and biguanides with rates of
psychiatric hospitalization and self-harm in individuals with serious mental
illness.</article-title><source><italic>JAMA Psychiatry. </italic></source><year>2019</year><volume>76</volume><issue>4</issue><fpage>382</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">30624557</pub-id></element-citation></ref><ref id="ref57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Hage</surname><given-names>W,</given-names></name><name><surname>Leman</surname><given-names>S,</given-names></name><name><surname>Camus</surname><given-names>V,</given-names></name><name><surname>Belzung</surname><given-names>C.</given-names></name></person-group><article-title>Mechanisms of antidepressant resistance.</article-title><source><italic>Front Pharmacol.</italic></source><year>2013</year><volume>4</volume><fpage>146</fpage><pub-id pub-id-type="pmid">24319431</pub-id></element-citation></ref><ref id="ref58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kennedy</surname><given-names>SH,</given-names></name><name><surname>Lam</surname><given-names>RW,</given-names></name><name><surname>McIntyre</surname><given-names>RS,</given-names></name><name><surname>et al.</surname><given-names/></name></person-group><article-title>Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016
Clinical Guidelines for the Management of Adults with Major Depressive Disorder:
Section 3.</article-title><source><italic>Pharmacological Treatments. Can J Psychiatry.</italic></source><year>2016</year><volume>61</volume><issue>9</issue><fpage>540</fpage><lpage>560</lpage><pub-id pub-id-type="pmid">27486148</pub-id></element-citation></ref><ref id="ref59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Touma</surname><given-names>KTB,</given-names></name><name><surname>Zoucha</surname><given-names>AM,</given-names></name><name><surname>Scarff</surname><given-names>JR.</given-names></name></person-group><article-title>Liothyronine for depression: a review and guidance for safety
monitoring.</article-title><source><italic>Innov Clin Neurosci.</italic></source><year>2017</year><volume>14</volume><issue>3-4</issue><fpage>24</fpage><lpage>29</lpage></element-citation></ref><ref id="ref60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parmentier</surname><given-names>T,</given-names></name><name><surname>Sienaert</surname><given-names>P.</given-names></name></person-group><article-title>The use of triiodothyronine (T3) in the treatment of bipolar
depression: A review of the literature.</article-title><source><italic>J Affect Disord.</italic></source><year>2018</year><volume>229</volume><fpage>410</fpage><lpage>414</lpage><pub-id pub-id-type="pmid">29331701</pub-id></element-citation></ref><ref id="ref61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schaffer</surname><given-names>A,</given-names></name><name><surname>McIntosh</surname><given-names>D,</given-names></name><name><surname>Goldstein</surname><given-names>BI,</given-names></name><name><surname>et al.</surname><given-names/></name></person-group><article-title>The canadian network for mood and anxiety reatments (CANMAT) task
force recommendations for the management of patients with mood disorders and
comorbid anxiety disorders.</article-title><source><italic>Ann Clin Psychiatry.</italic></source><year>2012</year><volume>24</volume><issue>1</issue><fpage>6</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">22303519</pub-id></element-citation></ref><ref id="ref62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katzman</surname><given-names>MA,</given-names></name><name><surname>Bleau</surname><given-names>P,</given-names></name><name><surname>Blier</surname><given-names>P,</given-names></name><name><surname>et al.</surname><given-names/></name></person-group><article-title>Canadian clinical practice guidelines for the management of anxiety,
posttraumatic stress and obsessive-compulsive disorders.</article-title><source><italic>BMC Psychiatry.</italic></source><year>2014</year><volume>14</volume><issue>Suppl 1</issue><fpage>S1</fpage><pub-id pub-id-type="pmid">25081580</pub-id></element-citation></ref><ref id="ref63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yildiz</surname><given-names>A,</given-names></name><name><surname>Nikodem</surname><given-names>M,</given-names></name><name><surname>Vieta</surname><given-names>E,</given-names></name><name><surname>Correll</surname><given-names>CU,</given-names></name><name><surname>Baldessarini</surname><given-names>RJ.</given-names></name></person-group><article-title>A network meta- analysis on comparative efficacy and all-cause
discontinuation of antimanic treatments in acute bipolar mania.</article-title><source><italic>Psychol Med.</italic></source><year>2015</year><volume>45</volume><fpage>299</fpage><lpage>317</lpage><pub-id pub-id-type="pmid">25036226</pub-id></element-citation></ref><ref id="ref64"><label>64</label><element-citation publication-type="journal"><article-title>Anti-inflammatoires non st&#x000e9;ro&#x000ef;diens (AINS) et complications
infectieuses graves &#x02013; Point d&#x02019;information.</article-title><source><italic/></source><comment>Available at:</comment></element-citation></ref><ref id="ref65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massoud</surname><given-names>F,</given-names></name><name><surname>Gauthier</surname><given-names>S.</given-names></name></person-group><article-title>Update on the pharmacological treatment of Alzheimer&#x02019;s
disease.</article-title><source><italic>Curr Neuropharmacol.</italic></source><year>2010</year><volume>8</volume><issue>1</issue><fpage>69</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">20808547</pub-id></element-citation></ref><ref id="ref66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>W,</given-names></name><name><surname>Gevonden</surname><given-names>M,</given-names></name><name><surname>Shaly</surname><given-names>A.</given-names></name></person-group><article-title>Preventionof post-traumatic stress disorder after trauma : current
evidence and future directions.</article-title><source><italic>Curr Psychiatry Rep.</italic></source><year>2016</year><fpage>18</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">26797860</pub-id></element-citation></ref><ref id="ref67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sijbrandij</surname><given-names>M,</given-names></name><name><surname>Kleiboer</surname><given-names>A,</given-names></name><name><surname>Bisson</surname><given-names>JI,</given-names></name><name><surname>Barbui</surname><given-names>C,</given-names></name><name><surname>Cuijpers</surname><given-names>P.</given-names></name></person-group><article-title>Pharmacological prevention of post-traumatic stress disorder and acute
stress disorder: a systematic review and meta-analysis.</article-title><source><italic>Lancet Psychiatry.</italic></source><year>2015</year><volume>2</volume><issue>5</issue><fpage>413</fpage><lpage>421</lpage><pub-id pub-id-type="pmid">26360285</pub-id></element-citation></ref><ref id="ref68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baldwin</surname><given-names>DS,</given-names></name><name><surname>Anderson</surname><given-names>IM,</given-names></name><name><surname>Nutt</surname><given-names>DJ,</given-names></name><name><surname>et al.</surname><given-names/></name></person-group><article-title>Evidence-based pharmacological treatment of anxiety disorders,
post-traumatic stress disorder and obsessive-compulsive disorder: a revision of
the 2005 guidelines from the British Association for
Psychopharmacology.</article-title><source><italic>J Psychopharmacol.</italic></source><year>2014</year><volume>28</volume><issue>5</issue><fpage>403</fpage><lpage>349</lpage><pub-id pub-id-type="pmid">24713617</pub-id></element-citation></ref><ref id="ref69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De la Torre</surname><given-names>JC.</given-names></name></person-group><article-title>Cerebral perfusion enhancing interventions: a new strategy for the
prevention of Alzheimer Dementia.</article-title><source><italic>Brain Pathol.</italic></source><year>2016</year><volume>26</volume><issue>5</issue><fpage>618</fpage><lpage>631</lpage><pub-id pub-id-type="pmid">27324946</pub-id></element-citation></ref><ref id="ref70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De la Torre</surname><given-names>JC.</given-names></name></person-group><article-title>Carotid artery ultrasound and echocardiography testing to lower the
prevalence of Alzheimer&#x02019;s disease.</article-title><source><italic>J Stroke Cerebreovasc Dis.</italic></source><year>2009</year><volume>18</volume><issue>4</issue><fpage>319</fpage><lpage>28</lpage></element-citation></ref><ref id="ref71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coca</surname><given-names>A,</given-names></name><name><surname>Monteagudo</surname><given-names>E,</given-names></name><name><surname>Com&#x000e9;nech</surname><given-names>M,</given-names></name><name><surname>Camafort</surname><given-names>M,</given-names></name><name><surname>Sierra</surname><given-names>C.</given-names></name></person-group><article-title>Can the treatment of hypertension in the middle-aged prevent dementia
in the elderly?</article-title><source><italic>High Blood Press Cardiovasc Prev.</italic></source><year>2016</year><volume>23</volume><issue>2</issue><fpage>97</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">27075454</pub-id></element-citation></ref><ref id="ref72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elamoshy</surname><given-names>R,</given-names></name><name><surname>Bird</surname><given-names>Y,</given-names></name><name><surname>Thorpe</surname><given-names>L,</given-names></name><name><surname>Moraros</surname><given-names>J.</given-names></name></person-group><article-title>Risk of depression and suicidality among diabetic patients: a
systematic review and meta-analysis.</article-title><source><italic>J Clin Med.</italic></source><year>2018</year><volume>7</volume><issue>11</issue><fpage>445</fpage><pub-id pub-id-type="doi">10.3390/jcm7110445.</pub-id></element-citation></ref><ref id="ref73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harriger</surname><given-names>JA,</given-names></name><name><surname>Thompson</surname><given-names>JK.</given-names></name></person-group><article-title>Psychological consequences of obesity: weigh bias and body image in
overweight and obese youth.</article-title><source><italic>Int Rev Psychiatry.</italic></source><year>2012</year><volume>24</volume><issue>3</issue><fpage>247</fpage><lpage>253</lpage><pub-id pub-id-type="pmid">22724646</pub-id></element-citation></ref><ref id="ref74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajan</surname><given-names>TM,</given-names></name><name><surname>Menon</surname><given-names>V.</given-names></name></person-group><article-title>Psychiatric disorders and obesity: a review of association
studies.</article-title><source><italic>J Postgrad Med.</italic></source><year>2017</year><volume>63</volume><issue>3</issue><fpage>182</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">28695871</pub-id></element-citation></ref></ref-list></back></article>